Pharmacological agents in development for diabetic macular edema

Pharmacological agents in development for diabetic macular edema

Abstract Background Diabetic macular edema (DME) is the leading cause of visual loss in patients with diabetic retinopathy. There has been a paradigm shift in the treatment of DME since the advent of anti-vascular endothelial growth factor (anti-VEGF) therapy. The safety and efficacy of anti-VEGF th...

Full description

Bibliographic Details
Main Authors: Mohammad Ali Sadiq, Muhammad Sohail Halim, Muhammad Hassan, Neil Onghanseng, Irmak Karaca, Aniruddha Agarwal, Rubbia Afridi, Yasir J. Sepah, Diana V. Do, Quan Dong Nguyen
Format: Article
Language:English
Published: BMC 2020-07-01
Series:International Journal of Retina and Vitreous
Subjects:
Vascular endothelial growth factor
Diabetic macular edema
Diabetic retinopathy
Online Access:http://link.springer.com/article/10.1186/s40942-020-00234-z

Internet

http://link.springer.com/article/10.1186/s40942-020-00234-z

Similar Items